Icon (NASDAQ:ICLR) Releases FY 2026 Earnings Guidance

Icon (NASDAQ:ICLR) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 10.000-11.000 for the period, compared to the consensus estimate of 11.330. The company issued revenue guidance of $7.9 billion-$8.2 billion, compared to the consensus revenue estimate of $7.9 billion.

Icon Stock Up 4.0%

Shares of ICLR stock traded up $4.60 during mid-day trading on Wednesday, hitting $118.45. 1,759,744 shares of the stock traded hands, compared to its average volume of 1,582,357. The stock has a market cap of $9.57 billion, a P/E ratio of 16.03, a P/E/G ratio of 3.05 and a beta of 1.23. The stock’s fifty day moving average is $111.14 and its two-hundred day moving average is $141.95. Icon has a 52-week low of $66.57 and a 52-week high of $211.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. TD Cowen upgraded shares of Icon from a “hold” rating to a “buy” rating and cut their price target for the stock from $183.00 to $120.00 in a report on Wednesday, February 18th. Robert W. Baird set a $119.00 price target on shares of Icon in a research note on Friday, February 13th. BMO Capital Markets upgraded Icon from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $100.00 to $130.00 in a report on Thursday, March 26th. Rothschild & Co Redburn set a $100.00 target price on shares of Icon and gave the stock a “neutral” rating in a research note on Tuesday, February 17th. Finally, Citigroup lowered their target price on shares of Icon from $200.00 to $120.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 11th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $147.67.

Hedge Funds Weigh In On Icon

Institutional investors have recently bought and sold shares of the company. Brooklyn Investment Group grew its position in Icon by 194.0% in the 3rd quarter. Brooklyn Investment Group now owns 1,273 shares of the medical research company’s stock valued at $223,000 after acquiring an additional 840 shares in the last quarter. Peapack Gladstone Financial Corp acquired a new position in shares of Icon during the second quarter worth about $212,000. Nicolet Advisory Services LLC acquired a new position in shares of Icon during the fourth quarter worth about $209,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of Icon during the third quarter worth about $207,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Icon by 15.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,185 shares of the medical research company’s stock worth $207,000 after buying an additional 163 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.